The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseKASL clinical practice guidelines: management of hepatitis CRecent advances in understanding hepatitis CMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsChronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic InfectionHCVIVdb: The hepatitis-C IRES variation databaseMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaReinventing HCV Treatment: Past and Future Perspectives.Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve PatientsEpidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus.Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms.Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in SpainLethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.New prospects for the treatment and prevention of hepatitis C in children.Hepatobiliary Quiz Answers-17 (2016).Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems.Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Cell transplantation as a non-invasive strategy for treating liver fibrosis.The expanding toolbox for hepatitis C virus research.Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Consolidation of molecular testing in clinical virology.Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing.Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Prevention and management of treatment failure to new oral hepatitis C drugs.Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.Hepatitis C virus resistance to the new direct-acting antivirals.
P2860
Q26740219-39E68F6B-8F72-401E-A9F5-184548DBA388Q26752433-55D9D4E1-5399-4DD1-AEC5-939DB39D30ACQ26752471-9E09FD46-ABC1-49A0-B673-05FF17C1373BQ26766136-77A57122-97FF-4CF2-8AD1-50745725693DQ26773321-05385D60-E4DC-416C-BECB-EB45F6F80AADQ26773585-5A36589F-DFCA-4FF5-9D23-EDECFE7525FCQ26775036-42E6924E-8991-45E3-B274-F4739023E6C9Q27468878-97321143-10CC-49CE-808A-A5DC35A4FF2DQ27469038-A7D5D60E-3146-4B27-B450-E5CE083E5EAEQ28079102-8BC74406-DB35-4AAF-A530-467568930CA7Q28552134-A75F4DA4-6540-4F4C-AFED-B63AF9E66933Q30241881-51CBA1D4-95C9-4E0F-B845-5AACA8C10862Q30843427-6D09F93C-1C6A-402C-A3F4-969ECCC20217Q31042796-EC10779A-6443-4EF2-9B03-9830B9CDF4CCQ33672648-EF4619D6-5320-4BE6-A4FF-E9E7BB027F0CQ33875539-8AA8067C-44E7-43BB-89AA-A94674572C07Q35975438-61F5758F-4638-4203-9183-6198A2768803Q35994877-F175C78F-1631-4547-BF6A-D70882FAC4B1Q36145716-B0DAE973-AAD7-4C77-92B1-470DBEEE23C3Q36148440-E1644A43-C806-41DB-801B-F234B9DAE8D3Q36166222-7F4F6A6D-ADBE-4410-8E4D-DEEED19BFA73Q36182240-883E4BE2-DCF2-4028-96A2-096E0DDA97ABQ36295405-567ED253-EF82-42D8-A5F6-4D9DFFAFB63BQ36519126-B8B99B07-B22B-4F32-BAB6-335BE8774E6AQ36608054-8E582291-A2B0-4FD7-879B-147DA38AF0D3Q36886795-5FC969CC-ADDA-4DCA-8C7B-C4DAB6E9BF63Q36933403-9BB573C3-3FD2-4D0D-A082-B27A9AA59888Q36988456-017A1536-E877-400D-8173-8BDBCC5205D5Q37148014-E65495CA-79A9-4DC8-A654-1559435B9525Q37310564-2C2405F8-D364-4E14-B68F-B274E54C04DDQ38675565-FB4BBB51-F80B-457D-89C4-803BB9FF5279Q38695199-0122BFCF-6B18-4CA5-803F-03FA124C0276Q38751552-7FED584A-E838-434B-947F-4EEB38227321Q38772047-C56C9E44-F7CD-4623-9095-75B4095F9D5CQ38779627-5C10CAEE-4BE8-4B75-86F3-D54F2F12741CQ38788003-754163D3-C969-4AEB-A9C0-F5428B97FEBBQ38811486-A0E4CCC3-8A9D-4ACC-AA49-1E89C7E71F63Q38826624-C140C64C-26E2-4B98-894A-A23F2C32B3B0Q38880996-D7755CD4-FA66-4EED-B03A-F2B49DF3B6D2Q38887954-7441AF9A-93C2-4D33-AFD4-996011E9E03C
P2860
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The importance of resistance t ...... nfection in clinical practice.
@en
type
label
The importance of resistance t ...... nfection in clinical practice.
@en
prefLabel
The importance of resistance t ...... nfection in clinical practice.
@en
P1476
The importance of resistance t ...... nfection in clinical practice.
@en
P2093
Christoph Sarrazin
P304
P356
10.1016/J.JHEP.2015.09.011
P577
2015-09-24T00:00:00Z